Johnson & Johnson vs Pfizer, Inc. — Stock Comparison
Johnson & Johnson (JNJ) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson scores ahead of Pfizer, Inc. on Q·Score (7 vs 6.1 out of 10), led by Quality (9.3 vs 5.7) and Sentiment (7.4 vs 5.2). Pfizer, Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for PFE (+14.3%) than for JNJ (+1.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
High-quality business with 26% return on equity and 21% profit margins.
⚠ earnings contracting 1% year-over-year.
Forward P/E of 8.9× is low relative to sector peers.
⚠ earnings contracting 10% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
JNJ vs PFE: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7/10 versus Pfizer, Inc. (PFE) at 6.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: JNJ or PFE?
Pfizer, Inc. (PFE) scores higher on Growth (5.1/10 vs 5/10). Johnson & Johnson reports revenue growth (6.6% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is JNJ or PFE more attractively valued?
Pfizer, Inc. (PFE) scores higher on Valuation (7.2/10 vs 6.5/10). JNJ trades at 20.7× P/E versus PFE at 8.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about JNJ vs PFE?
There are 22 analysts covering JNJ with a consensus price target of $270.59, and 26 analysts covering PFE with a consensus target of $28.75. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: JNJ or PFE?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 5.7/10). Net profit margin: JNJ at 21.5%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: JNJ or PFE?
Pfizer, Inc. (PFE) scores higher on Financial Health (7/10 vs 6.5/10). Market beta: JNJ at 0.23, PFE at 0.31. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of JNJ and PFE?
Johnson & Johnson (JNJ) has a market capitalisation of $639.9B, while Pfizer, Inc. (PFE) has a market cap of —. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do JNJ or PFE pay dividends?
JNJ pays a dividend yield of 2.01%, while PFE pays a dividend yield of 6.81%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →